Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC

Barclays PLC raised its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 125.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,886 shares of the company’s stock after buying an additional 59,016 shares during the quarter. Barclays PLC owned about 0.17% of Immunome worth $1,547,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of IMNM. FMR LLC lifted its position in Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares during the period. Janus Henderson Group PLC lifted its position in Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the period. Marshall Wace LLP lifted its position in Immunome by 228.5% in the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares during the period. Geode Capital Management LLC lifted its position in Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of recent research reports. Piper Sandler cut their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Stephens initiated coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Stock Performance

NASDAQ IMNM opened at $10.60 on Monday. The stock has a market cap of $661.62 million, a PE ratio of -1.31 and a beta of 1.90. Immunome, Inc. has a twelve month low of $8.97 and a twelve month high of $30.96. The firm has a 50-day simple moving average of $11.77 and a 200 day simple moving average of $12.99.

Insiders Place Their Bets

In other Immunome news, insider Robert Lechleider purchased 15,805 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Clay B. Siegall purchased 66,057 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the purchase, the chief executive officer now owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 102,862 shares of company stock worth $978,045 over the last quarter. Company insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.